The Rising Tide of Heart Disease in People Living with HIV
For decades, HIV has been understood as a virus attacking the immune system. But, a growing body of research reveals a significant and often overlooked consequence of HIV infection: an increased risk of cardiovascular disease (CVD). This isn’t simply a matter of people with HIV living longer and therefore experiencing age-related heart problems. The virus itself, and the persistent inflammation it causes, actively contributes to the development of heart disease.
Inflammation: The Common Thread
Persistent inflammation is now recognized as a key driver of CVD in people living with HIV (PLWH). Both HIV infection and CVD share inflammatory pathways. Innate immune cells, like monocytes, play a central role in this process. Studies reveal that even with well-controlled HIV infection, these cells exhibit altered gene expression, suggesting they may act as reservoirs for the virus and contribute to ongoing inflammation.
Monocytes and the Complicated Picture
Research focusing on monocytes – a type of white blood cell – has revealed intriguing details. Two subtypes, non-classical monocytes (NCM) and intermediate monocytes (IM), are particularly important. While IM gene expression isn’t dramatically affected by HIV or CVD alone, the combination of both triggers a distinct gene transcription signature. Interestingly, this signature can be lessened with lipid-lowering treatments.
NCMs, show altered gene expression in PLWH regardless of whether they have CVD. The most significant changes are observed in individuals with both HIV and CVD, highlighting the synergistic effect of these conditions. Some of the genes upregulated in these patients are potential targets for drug therapies, including LAG3 (CD223).
Coronary Plaque and Immune Activation
Recent studies demonstrate a high prevalence of coronary plaque – cholesterol deposits in the arteries – among PLWH, even those with well-controlled HIV. While most plaque is limited, its presence is linked to higher levels of markers indicating immune function and inflammation. This suggests that immune activation is a significant factor in the development of atherosclerosis, the buildup of plaque in the arteries.
Future Trends and Research Directions
Several key areas are emerging in the research landscape:
- Personalized Medicine: Identifying specific gene expression signatures in monocytes could lead to personalized treatment strategies for PLWH at risk of CVD.
- Targeting Inflammation: Developing therapies specifically designed to reduce inflammation in PLWH may prove effective in preventing or slowing the progression of heart disease.
- Longitudinal Studies: Continued long-term studies, like the REPRIEVE trial, are essential to understand the evolving relationship between HIV, inflammation, and CVD.
- Impact of Early Intervention: Research is needed to determine if early intervention with lipid-lowering medications and lifestyle modifications can mitigate the risk of CVD in PLWH.
The Role of Women’s Health
Studies, such as those conducted within the Women’s Interagency HIV Study, are specifically examining the impact of HIV and CVD in women. This is crucial, as cardiovascular disease manifests differently in women than in men, and the interplay with HIV may further complicate the picture.
Frequently Asked Questions
- Is heart disease more common in people with HIV?
- Yes, people living with HIV have a significantly higher risk of cardiovascular disease compared to those without HIV.
- What causes this increased risk?
- Persistent inflammation caused by HIV infection is a major contributing factor, along with potential effects of antiretroviral therapy and traditional risk factors.
- Can treatment assist reduce the risk?
- Yes, effective antiretroviral therapy, lipid-lowering medications, and a healthy lifestyle can all help manage risk factors and reduce the likelihood of developing CVD.
- Are there specific tests to monitor heart health in PLWH?
- Healthcare providers may apply carotid artery ultrasound to detect subclinical CVD, as well as standard tests like cholesterol levels and blood pressure monitoring.
Understanding the link between HIV and heart disease is vital for improving the health and well-being of PLWH. By focusing on inflammation, personalized medicine, and continued research, we can work towards a future where cardiovascular complications are minimized.
Learn More: Explore additional resources on HIV and cardiovascular health at HIV.gov and The Cardiology Advisor.
Have questions or thoughts on this topic? Share your comments below!
